IN8bio, Inc. INAB 深 沪
等待开盘 06-26 09:30:00 美东时间
1.3657
-0.104
-7.10%
华盛通- 最 高1.5301
- 今 开1.47
- 成交量 8.08万股
- 最 低 1.34
- 昨 收 1.47
- 总市值 2.57万
- 52周最高 2.73
- 市盈率 静 --
- 换手率 428.74%
- 52周最低 1.17
- 委 比 61.06%
- 总股本 1.88万
- 历史最高 10.319
- 量 比 3.05
- 振 幅 12.93%
- 历史最低 0.101
- 每 手 1
- 风险率 0.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多IN8bio Publishes Nature Communications Review Highlighting Engineered γδ T Cell Cancer Therapies And Combination Treatment Advances
IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the
06-03 20:39
IN8bio Q1 EPS $(0.26) Beats $(0.69) Estimate
IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.69) by 62.32 percent. This is a 87.96 percent increase over losses of $(2.16) per share from the same
05-08 04:52
IN8bio Promotes Kate Rochlin To President, COO, Effective Immediately
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the promotion of Kate
02-09 21:08
广东省阳江市市场监督管理局关于2025年第2期食品安全抽检结果的公示
近期，阳江市市场监督管理局对全市食品经营单位开展食品安全（普通预包装食品销售环节、食用农产品销售环节,不含餐饮环节）监督抽检，共抽取180批次。经检验，发现其中...
2025-07-03 16:35
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
Pat. 009 with grade 4 IDH-mutant glioma survives 4 years after INB-200 gamma-delta T cell therapy, surpassing standard outcomes. INB-200 shows extended mPFS of 16.1 months, highlighting potential for treating aggressive cancers.
2025-06-09 11:00
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
IN8bio announced new long-term clinical data for INB-200 in patients with newly diagnosed glioblastoma multiforme (GBM), showing a median progression-free survival (mPFS) of 16.1 months, more than double the standard-of-care (SOC) Stupp protocol's 6.9 months. The treatment was well-tolerated with no serious toxicities, and four patients remained alive and progression-free for over two years. The company will host a conference call with principal investigator Dr. Burt Nabors today at 8:30am EDT.
2025-06-02 11:30
万春医药盘中异动 股价大跌5.83%报2.10美元
北京时间2024年11月05日03时10分，万春医药（BYSI.us）股票出现波动，股价快速下挫5.83%。截至发稿，该股报2.10美元/股，成交量1.5265万股，换手率0.04%，振幅3.14%。 最近的财报数据显示，该股实现营业收入1000000.00美元，净利润-7.26百万美元，每股收益-0.19美元，毛利--，市盈率-5.32倍。 机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。 万春医药股票所在的生物技术行业中，整体跌幅为0.35%。其相关个股中，Neurogene Inc.、Tenaya Therapeutics, Inc.、Disc Medicine, Inc....
2024-11-05 03:10
